sitagliptin OR saxagliptin — Competitive Intelligence Brief

sitagliptin OR saxagliptin (sitagliptin OR saxagliptin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

phase 3 DPP-4 inhibitor DPP-4 Diabetes Small molecule

Target snapshot

sitagliptin OR saxagliptin (sitagliptin OR saxagliptin) — University of Sao Paulo General Hospital. Sitagliptin and saxagliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase the levels of incretin hormones to enhance glucose-dependent insulin secretion.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
sitagliptin OR saxagliptin TARGET	sitagliptin OR saxagliptin	University of Sao Paulo General Hospital	phase 3	DPP-4 inhibitor	DPP-4
CSII followed by Lina+MET	CSII followed by Lina+MET	Sun Yat-sen University	marketed	Insulin therapy combined with DPP-4 inhibitor and biguanide	Insulin receptor (CSII); DPP-4 enzyme (linagliptin); mitochondrial glycerophosphate dehydrogenase (metformin)
Janumet, Lantus	Janumet, Lantus	Chinese University of Hong Kong	marketed	DPP-4 inhibitor + biguanide (Janumet); long-acting basal insulin (Lantus)	DPP-4 enzyme, metformin (AMPK pathway), insulin receptor (Lantus)
SGLT2i+Metformin+Cofrogliptin	SGLT2i+Metformin+Cofrogliptin	Huazhong University of Science and Technology	marketed	SGLT2 inhibitor + Biguanide + DPP-4 inhibitor (fixed-dose combination)	SGLT2, mitochondrial complex I, DPP-4
MET + Vildagliptin Group	MET + Vildagliptin Group	Hospital de Clinicas de Porto Alegre	marketed	Combination antidiabetic agent (biguanide + DPP-4 inhibitor)	Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)
Anagliptin BID Treatment	Anagliptin BID Treatment	JW Pharmaceutical	marketed	DPP-4 inhibitor	Dipeptidyl peptidase-4 (DPP-4)
Pioglitazone + Alogliptin	Pioglitazone + Alogliptin	Celltrion Pharm, Inc.	marketed	Thiazolidinedione + DPP-4 inhibitor combination	PPAR-γ and DPP-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

1. Merck Sharp & Dohme LLC · 5 drugs in this class
2. Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
3. AstraZeneca · 4 drugs in this class
4. LG Life Sciences · 2 drugs in this class
5. Tanabe Pharma Corporation · 2 drugs in this class
6. Ain Shams University · 2 drugs in this class
7. Ono Pharmaceutical Co. Ltd · 2 drugs in this class
8. Cinnagen · 1 drug in this class
9. GRADE Study Group · 1 drug in this class
10. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class